Forest lab sues Glenmark Pharma for Savella patent infringement

11 Feb 2014 Evaluate

Forest lab has sued Glenmark Pharma for Savella patent infringement. New York-based Forest has claimed that that Glenmark's abbreviated new drug application for the sale of milnacipran hydrochloride in 12.5, 25, 50 and 100 milligram dosage strengths would infringe on several patents it holds that indicate methods for treating fibromyalgia. Those patents are not due to expire until at least 2021.

Savella, or milnacipran hydrochloride, is a serotonin-norepinephrine reuptake inhibitor used to treat fibromyalgia, a disease characterized by chronic widespread pain throughout the body.

Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1540.70 -52.20 (-3.28%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.